QuantaMatrix Inc.
Research QuantaMatrix Inc. (317690.KQ) on Bullrun: market cap KRW 43.69B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker317690.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryMedical Devices
- CurrencyKRW
- Market capKRW 43.69B
- Financial periodQ2 2026
- RevenueKRW 646.15M
- Net income-KRW 3.81B
- Free cash flow-KRW 3.96B
- Gross margin-0.4%
Valuation Snapshot
latest market cap is KRW 43.69B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 43.69B | n/a | n/a | n/a |
Dividend history
About QuantaMatrix Inc.
QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is QuantaMatrix Inc.'s market cap?
QuantaMatrix Inc.'s market capitalization is KRW 43.69B.
What does QuantaMatrix Inc. do?
QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. QuantaMatrix Inc. was founded in 2010 and is based in Seoul, South Korea.